1-[5-[(2R)-2-(5-fluoro-2-methoxy-3-pyridinyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]imidazol-2-amine
C19H19FN8O — CID 156771478
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[5-[(2R)-2-(5-fluoro-2-methoxy-3-pyridinyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]imidazol-2-amine
1-[5-[(2R)-2-(5-fluoro-2-methoxy-3-pyridinyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]imidazol-2-amine (PubChem CID 156771478) has the molecular formula C19H19FN8O and a molecular weight of 394.41 g/mol. Its IUPAC name is 1-[5-[(2R)-2-(5-fluoro-2-methoxy-3-pyridinyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]imidazol-2-amine.
Molecular Properties
| Compound Name | 1-[5-[(2R)-2-(5-fluoro-2-methoxy-3-pyridinyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]imidazol-2-amine |
|---|---|
| PubChem CID | 156771478 |
| Molecular Formula | C19H19FN8O |
| Molecular Weight | 394.41 g/mol |
| Exact Mass | 394.17 |
| IUPAC Name | 1-[5-[(2R)-2-(5-fluoro-2-methoxy-3-pyridinyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]imidazol-2-amine |
| SMILES | COc1ncc(F)cc1[C@H]1CCCN1c1ccn2ncc(-n3ccnc3N)c2n1 |
| InChI | InChI=1S/C19H19FN8O/c1-29-18-13(9-12(20)10-23-18)14-3-2-6-26(14)16-4-7-28-17(25-16)15(11-24-28)27-8-5-22-19(27)21/h4-5,7-11,14H,2-3,6H2,1H3,(H2,21,22)/t14-/m1/s1 |
| InChIKey | APCYAHIBLDCHND-CQSZACIVSA-N |
| XLogP | 2.38 |
| TPSA | 99.39 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 394.41 |
| LogP ≤ 5 | 2.38 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156771478 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.